Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 17/20 | 0.64 |
| ▸ | METAP1 | P53582 | 9/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564913 | 0.83 | METAP2 (0.53) | METAP2METAP1 | |
| SCHEMBL6937335 | 0.83 | METAP2 (0.46) | METAP2METAP1 | |
| SCHEMBL6939440 | 0.83 | METAP2 (0.56) | METAP2METAP1 | |
| SCHEMBL6563019 | 0.81 | METAP2 (0.54) | METAP2METAP1 | |
| SCHEMBL6939035 | 0.80 | METAP2 (0.64) | METAP2METAP1 | |
| SCHEMBL7075750 | 0.80 | METAP2 (0.49) | METAP2METAP1 | |
| SCHEMBL6937626 | 0.80 | METAP2 (0.47) | METAP2METAP1 | |
| SCHEMBL6565042 | 0.79 | METAP2 (0.51) | METAP2METAP1 | |
| SCHEMBL6937951 | 0.79 | METAP2 (0.46) | METAP2METAP1 | |
| SCHEMBL6485535 | 0.78 | METAP2 (1.00) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885F2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.